關於 dengue fever vaccine takeda ，我們在網路上蒐集到這些相關的討論、資訊與評價

#11. EMA committee endorses Takeda dengue vaccine candidate

The vaccine, TAK-003, was endorsed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ...

#12. EU Regulator Recommends Clearing Takeda's Dengue Vaccine

Studies showed Takeda's vaccine was about 84% effective in preventing people from being hospitalized with dengue and about 61% effective in ...

#13. Takeda Receives Positive CHMP Opinion ... - Business Wire

In August 2022, Takeda's dengue vaccine, known as QDENGA ® ▽ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), was approved by the ...

#14. Takeda targets global vaccine market after approval of ...

Takeda has said approval of its dengue fever vaccine in Indonesia marks a big step towards the company's goal of creating a global vaccine ...

#15. GDAC statement on Takeda's announcement about their ...

GDAC statement on Takeda's announcement about their Dengue vaccine phase 3 ... by dengue virus serotype, pre-vaccination dengue infection status (i.e., ...

#16. Dengue vaccine: Takeda's QDENGA approved in Indonesia

QDENGA is the only dengue vaccine approved in Indonesia for use in individuals regardless of previous dengue exposure and without the need for ...

#17. Takeda's dengue vaccine expected to be approved ... - Reuters

TOKYO, Aug 17 (Reuters) - Takeda Pharmaceutical Co's (4502.T) experimental vaccine for dengue fever is expected to be approved in Indonesia ...

#18. Takeda apparently to become first Japanese firm to sell ...

The firm said its vaccine for dengue fever has been approved in Indonesia, and that it is additionally eyeing the possibility of its use in ...

#19. European Medicines Agency Recommends Approving ...

The trials also found the new Takeda vaccine to be more protective for children and people aged 45 and older than the existing dengue vaccine, ...

#20. With Approval For Dengue Vaccine, Takeda May Find It ...

Qdenga is the only dengue vaccine approved in Indonesia for use in ... the approval for Takeda's dengue fever vaccine in Indonesia marks a ...

#21. Takeda's dengue vaccine candidate delivers continued ...

Takeda has announced that its dengue vaccine, TAK-003, prevented 84% of hospitalised cases and 61% of symptomatic cases. Furthermore, there were ...

#22. Takeda's tetravalent dengue vaccine (TAK-003) receives first ...

Takeda's tetravalent dengue vaccine demonstrated continued overall protection against dengue illness and hospitalization three years after ...

#23. Global First Approval For Takeda's Dengue Vaccine, In ... - Scrip

Takeda's dengue vaccine Qdenga has received its global first approval in Indonesia, as Qdenga, also marking the first time for the firm to ...

#24. Takeda gets positive CHMP opinion recommending approval ...

“We are one step closer towards the approval of a dengue vaccine that ... Dengue is the second most diagnosed cause of fever in travelers ...

#25. Efficacy, Safety and Immunogenicity of Takeda's Tetravalent ...

The vaccine being tested in this study is Takeda's Tetravalent Dengue Vaccine Candidate (TDV). TDV is being tested to protect people against dengue fever ...

#26. All Aboard! Takeda's Dengue Fever Vaccine Holds Up Over ...

Takeda is targeting dengue with TAK-003, a tetravalent vaccine candidate based on a live-attenuated serotype 2 virus. The vaccine is being ...

#27. Guliang Xia, MD, PhD'S Post - LinkedIn

Cheers to the Vaccines group and the legacy of Tachi Yamada! FiercePharma: Takeda's dengue fever vaccine approved in Indonesia. https://lnkd.in/ez8Btsjs ...

#28. DEN-204-Protocol-Amend4_Redacted

schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in healthy ... Dengue fever is caused by infection with the dengue virus (DENV), ...

#29. Takeda Dengue Vaccine Recommended for Approval by ...

Takeda 's dengue vaccine, known as QDENGA (TAK-003), was approved in August of this year by the Indonesia National Agency for Drug and Food ...

#30. (PDF) Three-year Efficacy and Safety of Takeda's Dengue ...

Background: Takeda's live attenuated tetravalent dengue vaccine candidate ... Clinical Management of Dengue & Dengue Haemorrhagic Fever, ...

#31. Takeda's dengue vaccine candidate recommended ... - PMLiVE

Takeda's dengue vaccine candidate recommended for approval by CHMP. Dengue disease causes around 390 million infections and 500,000 ...

#32. Takeda's Qdenga vaccine for dengue sees first approval in ...

Takeda Pharmaceutical Co. Ltd.'s dengue fever vaccine, Qdenga, was approved in Indonesia Aug. 23, making it the first global approval for ...

#33. Takeda building Dengue fever vaccine plant

Takeda building Dengue fever vaccine plant. December 1, 2016|Biopharma Reporter. Contact · Visit us · Jobs · Sign up for news · DGHI Communications Toolkit.

#34. Takeda: Dengue Vaccine Candidate Works Without Big Safety ...

Drugmaker Takeda announced Thursday that its dengue vaccine candidate, TAK-003, prevented 84% of hospitalized dengue cases and 61% of ...

#35. EU regulator recommends clearing Takeda's dengue vaccine

FILE – In this Jan. 27, 2016, file photo, an Aedes aegypti mosquito known to carry the Zika virus and the Dengue fever, is photographed ...

#36. EMA Announces Positive Indication for Takeda's Dengue ...

The European Medicines Agency (EMA) human medicines committee (CHMP) announced a positive indication for Takeda's dengue tetravalent vaccine ( ...

#37. Takeda will be the first Japanese pharmaceutical company to ...

Takeda Pharmaceutical Co., Japan's leading drug manufacturer, yesterday announced the approval of its dengue fever vaccine by Indonesian ...

#38. Takeda Receives Positive CHMP Opinion ... - ANSA

In August 2022, Takeda's dengue vaccine, known as QDENGA ® ? ... each of which can cause dengue fever or severe dengue.

#39. Takeda's dengue data spell more bad news for Sanofi | Evaluate

Sanofi was already on shaky ground with its dengue fever vaccine, Dengvaxia. Now the product looks likely to be relegated to the sidelines ...

#40. Takeda announces positive data from dengue vaccine study

Takeda has announced its dengue vaccine candidate TAK-003 managed to prevent fever caused by all four subtypes of the virus in a Phase III ...

#41. Dengue fever vaccine still protects after three years - Freethink

The long-term human safety and efficacy trial raises hopes for an effective way to fight breakbone fever. ... Japanese pharma concern Takeda has ...

#42. Takeda Receives Positive CHMP Opinion Recommending ...

3,4 Dengue is the second most diagnosed cause of fever in travelers returning ... In August 2022, Takeda's dengue vaccine, known as QDENGA^® ...

#43. Takeda claims PhIII success in dengue vaccine months after ...

Takeda is one stride closer to reaching the sizable market waiting for dengue vaccines as it reports positive top-line results from a ...

#44. Long-Term Study Reaffirms Potential of Takeda's Dengue ...

Takeda has touted the potential of its Dengue vaccine for several ... for Clinical Management of Dengue and Dengue Hemorrhagic Fever in Sri ...

#45. Takeda's Dengue Vaccine Candidate ... - PharmiWeb.com

Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial.

#46. Takeda's dengue vaccine expected to be approved ... - Nasdaq

Takeda Pharmaceutical Co's experimental vaccine for dengue fever is expected to be approved in Indonesia soon, Japan's Nikkei newspaper ...

#47. Singapore may have access to new dengue vaccine in ... - CNA

Currently, Dengvaxia is the world's only approved vaccine for dengue - but it is only for those who have had a previous infection. Takeda's ...

#48. Takeda Says Its Dengue Vaccine Candidate Prevents Illness ...

Takeda's dengue vaccine candidate (TAK-003) prevented 83.6% of ... Center for Clinical Management of Dengue and Dengue Haemorrhagic Fever, ...

#49. Efficacy of Dengue Vaccines in the Prevention of Severe ...

One vaccine - the chimeric yellow fever-dengue-tetravalent dengue vaccine (CYD-TDV) - has been approved for use in some populations, and several ...

#50. Takeda's Dengue Vaccine Shows Promise - WSJ

Takeda's Dengue Vaccine Shows Promise · Latest data from trial shows treatment was effective in preventing children from dengue illnesses and ...

#51. Takeda Pharmaceutical's dengue vaccine shows promise in ...

Takeda Pharmaceutical's dengue vaccine shows promise in trials ... public health benefits against dengue fever and hospitalisation.”.

#52. Takeda's dengue vaccine candidate offers protection against ...

Takeda's dengue vaccine candidate offers protection against dengue fever in clinical trial. TAK-003 is currently undergoing regulatory review for potential ...

#53. Takeda targeting broader population for dengue vaccine

Takeda Pharmaceutical Co. Ltd. executives remained tight-lipped on plans for its experimental dengue fever vaccine during its earnings ...

#54. Takeda's Dengue Vaccine Candidate ... - Financial Post

It is caused by any of four dengue virus serotypes, each of which can cause dengue fever or severe dengue. The prevalence of individual ...

#55. MA-TAKEDA-PHARMACEUTICAL | Business Wire - Via Ritzau

In August 2022, Takeda's dengue vaccine, known as QDENGA ® ▽ (Dengue Tetravalent ... each of which can cause dengue fever or severe dengue.

#56. EU recommends approval of Takeda's dengue vaccine

Regulatory reviews will also advance in dengue-endemic countries in Latin America and Asia. The incidence of dengue fever has increased ...

#57. Takeda's Dengue vaccine candidate provides extended ...

“Through four and a half years, TAK-003 demonstrated 84.1 percent vaccine efficacy (VE) (95% CI: 77.8, 88.6) against hospitalized dengue, with ...

#58. Takeda Receives Positive CHMP ... - The Bakersfield Californian

3,4 Dengue is the second most diagnosed cause of fever in travelers returning ... In August 2022, Takeda's dengue vaccine, known as QDENGA ...

#59. Takeda's dengue vaccine shows promising results against all ...

... vaccine increased seropositivity rates against dengue virus types 3 and 4 in children who were not previously exposed to infection.

#60. Dengue vaccine trials of Japan's Takeda show protection ...

Japan's Takeda Pharmaceutical Company Limited (Takeda) on Wednesday said its trials on the dengue vaccine candidate (TAK-003), including in ...

#61. Promising Results For Takeda's Dengue Vaccine

Dengue fever is a painful, debilitating mosquito-borne disease caused by any one of four closely related virus serotypes. Forty percent of the ...

#62. Potential Impact of Takeda's Dengue ... - World Pharma Today

It is caused by any of four dengue virus serotypes, each of which can cause dengue fever or severe dengue. The prevalence of individual serotypes varies across ...

#63. Takeda's dengue vaccine candidate ... - Express Pharma

... against dengue fever through 4.5 years in pivotal clinical trial ... Takeda yesterday announced that its dengue vaccine candidate, ...

#64. Takeda's Dengue Vaccine Gets EU Endorsement for Wider Use

Each year up to 400 million people get infected with dengue, 100 million people get sick from the infection and 40,000 die from severe dengue, according to the ...

#65. Encouraging signs for Takeda's dengue vaccine program

“Infection with one dengue serotype makes subsequent infection with a different serotype a major risk factor for severe disease, hence the need ...

#66. Hope on the horizon in troubled journey to develop dengue ...

She added that where Sanofi used yellow fever virus as the backbone, Takeda's approach uses dengue. This was “shown to generate robust T cell ...

#67. Dengue vaccine development: status and future - RKI

a second dengue infection with a dengue ... vaccine with a yellow fever 17D back- bone, is the first dengue ... apart, the Takeda vaccine is currently be-.

#68. Takeda first Japanese firm to sell dengue vaccine abroad

Takeda Pharmaceutical said Tuesday that its vaccine for dengue fever has been approved in Indonesia. This will be the first global launch of ...

#69. Takeda's Dengue Vaccine Candidate Provides ... - bionity.com

Takeda announced that its dengue vaccine candidate, TAK-003, prevented 84% ... Continued Protection Against Dengue Fever Through 4.5 Years.

#70. Takeda dengue vaccine candidate show long term safety ...

Takeda will seek an indication for TAK-003 for the prevention of dengue disease in individuals four to 60 years of age, regardless of previous ...

#71. Takeda's dengue vaccine TAK-003 shows efficacy through 4.5 ...

The study, dubbed TIDES, is evaluating two doses of the vaccines, against placebo to prevent laboratory-confirmed symptomatic dengue fever of ...

#72. Takeda apparently to become 1st Japan's firm to sell vaccine ...

Takeda Pharmaceutical Co., Japan's biggest drug maker, said Tuesday that its vaccine for dengue fever was appr…

#73. Takeda's dengue vaccine candidate prevents 84 per cent ...

The TIDES trial is Takeda's largest interventional clinical trial to date, enrolling more than 20,000 healthy children and adolescents four to ...

#74. Efficacy of a Tetravalent Dengue Vaccine in Healthy Children ...

A tetravalent dengue vaccine based on a yellow fever virus “backbone,” CYD-TDV (Dengvaxia, Sanofi Pasteur), has been licensed in several ...

#75. Takeda Dengue vaccine TAK-003 provides continued ...

New Delhi: Takeda has announced that its dengue vaccine candidate, TAK-003, ... protection against dengue fever through 4.5 years in trial.

#76. EMA accepts submission for Takeda's dengue vaccine ...

TAK-003 is a tetravalent dengue vaccine candidate based on a live-attenuated dengue serotype 2 virus, which provides the genetic backbone for ...

#77. Takeda Symposium | Asian Dengue Voice and Action

PH needs vaccine for dengue as disease remains a threat despite drop in cases. July 4, 2021. MANILA, Philippines — Dengue fever cases ...

#78. Planning ahead for access to the dengue vaccine

Takeda has strong project-specific access plans for some late-stage R&D projects. One such project is its dengue vaccine (TAK-003). Takeda intends to file for ...

#79. Takeda's Dengue Vaccine Candidate Shows Long-Term ...

A two-dose series of Takeda's dengue fever vaccine candidate, TAK-003, has demonstrated strong protective effects in the company's long-term ...

#80. Characterization of the cell-mediated immune response to ...

Infection with any of the four dengue virus serotypes (DENV-1, DENV-2, DENV-3, ... The tetravalent dengue vaccine candidate, TAK-003 (Takeda ...

#81. Takeda's Dengue Vaccine Candidate

Development of Takeda's dengue vaccine candidate ... Protects against infection with all four dengue virus serotypes and all severities of dengue disease.

#82. Efficacy of the TAK-003 Vaccine for Protection Against ...

At 3 years, the TAK-003 vaccine from Takeda remained effective at protecting against symptomatic dengue fever among children and adolescents ...

#83. Potential Impact of Takeda's Dengue Vaccine ... - Taiwan News

Takeda's dengue vaccine candidate (TAK-003) prevented 83.6% of ... Center for Clinical Management of Dengue and Dengue Haemorrhagic Fever, ...

#84. Current Development and Challenges of Tetravalent Live ...

Takeda's dengue vaccine (TAK-003) candidate is based on the molecularly characterized live attenuated DENV-2 PDK-53 strain (TDV-2). Three other recombinant ...

#85. Takeda's dengue vaccine prevents hospitalisations in TIDES ...

Takeda's tetravalent dengue vaccine candidate, TAK-003, offers protection against hospitalisation and illness in Phase III trial. ... TAK-003 ...

#86. Takeda to Submit Regulatory Filing for New Dengue Vaccine ...

The data also showed dengue, which often developed into a hemorrhagic fever, is particularly fatal to children. According to the ministry data, ...

#87. Dengue clinches Takeda deal | Nature Biotechnology

Takeda Pharmaceutical of Osaka, Japan, has acquired vaccine developer ... a tetravalent recombinant dengue fever vaccine in phase 2 testing, ...

#88. New data on Takeda's dengue vaccine look promising, but ...

New data about the effectiveness of Takeda Pharmaceutical's experimental dengue vaccine will likely raise more concerns among the many ...

#89. Dengue endemic vaccines: awaiting Takeda's TAK-003

A Sanofi Pasteur vaccine (CYD-TDV Dengvaxia®) has been licensed since 2015 for the prevention of disease caused by all four dengue virus ...

#90. For India, finally a dengue vaccine in sight | Mint

Takeda is in talks with the Indian drug regulator to seek approval for its dengue vaccine, which has been shown to prevent hospitalizations ...

#91. Takeda plans German plant to support dengue vaccine roll-out

Dengue fever vaccine mosquito. Takeda is investing more than €100m in a manufacturing facility in Germany that will produce its vaccine for ...

#92. Three years efficacy and safety of Takeda's dengue vaccine ...

Takeda's live attenuated tetravalent dengue vaccine candidate (TAK-003) is under evaluation in a long-term clinical trial across eight ...

#93. Dengue vaccine from Takeda shows promise - News Medical

Results from the vaccine trial showed that the vaccine was 80 percent effective in preventing dengue infections among the included participants ...

#94. Takeda's dengue vaccine meets goal in Phase 3 study

In some Latin American and Asian countries including Brazil, the Philippines and Thailand, dengue fever is endemic and a leading cause of ...

#95. Prof Ooi Eng Eong on dengue vaccines - YouTube

Dengue cases continue to swell in Singapore in the worst flare-up since 2020. Japanese pharmaceutical company Takeda will present a dengue ...

#96. First Approval for Takeda Dengue Vaccine - PharmaBoardroom

Takeda gets a first approval for QDENGA, its dengue vaccine, which has been given the green light by the Indonesian National Agency for Drug and Food ...

#97. Takeda Dengue Vaccine: Clinical Trials, Updates and Efficacy

Dengue fever is a destructive mosquito-borne flavivirus with about half of the world's population at risk. There are roughly 390 million ...